高级搜索
鼻咽癌外照射联合高剂量率腔内后装治疗近期疗效观察[J]. 肿瘤防治研究, 2000, 27(04): 305-306. DOI: 10.3971/j.issn.1000-8578.688
引用本文: 鼻咽癌外照射联合高剂量率腔内后装治疗近期疗效观察[J]. 肿瘤防治研究, 2000, 27(04): 305-306. DOI: 10.3971/j.issn.1000-8578.688
The Short-term Results of Nasopharyngeal Carcinoma Treated by Combined External Irradiation and Intracayitary Brachytherapy of the High Dose Rate[J]. Cancer Research on Prevention and Treatment, 2000, 27(04): 305-306. DOI: 10.3971/j.issn.1000-8578.688
Citation: The Short-term Results of Nasopharyngeal Carcinoma Treated by Combined External Irradiation and Intracayitary Brachytherapy of the High Dose Rate[J]. Cancer Research on Prevention and Treatment, 2000, 27(04): 305-306. DOI: 10.3971/j.issn.1000-8578.688

鼻咽癌外照射联合高剂量率腔内后装治疗近期疗效观察

The Short-term Results of Nasopharyngeal Carcinoma Treated by Combined External Irradiation and Intracayitary Brachytherapy of the High Dose Rate

  • 摘要: 目的 观察鼻咽癌外照射联合高剂量率腔内后装治疗的近期疗效和反应。从1996年8月至1998年8月,74例鼻咽癌患者中,16例早期鼻咽癌外照射DT52-62GY/5.2-6.2W,腔内治疗DT16-24GY/2-3W/2-3T,38例外照射DT70GY/7W后,鼻咽肿块残存,加腔内治疗DT6-16GY/1-2W/1-2T,20例局部复发外照射DT40-60GY/4-6W后,腔内治疗DT16-30GY/2-3W/2-3T。结果 腔内治疗剂量大于24GY和复发再治者粘膜反应较重,局部残存者消退率100%,局部复发再治消退率90%,1年局部控制率93.3%。结论 适当的腔内治疗可提高局部消退率和控制率,且无严重的并发症发生。   

     

    Abstract: ObjectiveTo investigate short-term effect of nasopharyngeal carcinoma treated by combined external irradiation and intracavitary brachytherapy of the high dose rate. Methods From August 1996 to August 1998,among 74 patienis with NPC,16 cases received external beam for 52~62GY/5.2~6.2W,followed by intracavitary brachytherapy for 16~24GY/2~3T/2~3W and 38 cases taking inteacavitary brachytherapy to local lump remain for 6~16GY/1~2T/1~2W after receiving external beam for 70GY/7W,20 patients with local failure received external beam for 40~60GY/4~6W,followed by intracavitary brachytherapy for 16~30GY/2~3T/2~3W. Results Intracavitary brachytherapy dose exceed 24GY and recrudescence patients with severe mucous membrane reaction,patients with local remain tumour having 100%,detumescence rate and ones with local failure having 90% detumescence rate,tumour control rate being 93.3% for one year. Conclusion Poper intracavity brachytereraph can improve local detumescence rate and control rate and without sever radiation cure syndrome.

     

/

返回文章
返回